TALEN

Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs

Retrieved on: 
水曜日, 4月 10, 2024
Molecular Therapy, Brain, Euronext Growth, Therapy, TALEN, Research, DSM-IV codes

NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy, demonstrating that TALEN-mediated intron editing of hematopoietic stem and progenitor cells (HSPCs) enables transgene expression restricted to the myeloid lineage.

Key Points: 
  • NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy, demonstrating that TALEN-mediated intron editing of hematopoietic stem and progenitor cells (HSPCs) enables transgene expression restricted to the myeloid lineage.
  • This approach could unlock new therapeutic avenues for the treatment of inborn metabolic diseases as well as neurological diseases that require delivery of therapeutics to the brain.

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)

Retrieved on: 
木曜日, 10月 12, 2023
PIK3CD, TALEN, Euronext Growth, Research, Mythic Imagination Institute, Vaccine, Management, Cellectis

NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy – Methods & Clinical Development, demonstrating the efficacy of its TALEN-mediated gene correction of mutated PIK3CD gene in APDS1 T-cells.

Key Points: 
  • NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy – Methods & Clinical Development, demonstrating the efficacy of its TALEN-mediated gene correction of mutated PIK3CD gene in APDS1 T-cells.
  • The research work described in this article was jointly conducted by Imagine Institute and Cellectis teams.

Allogeneic CAR Cell Therapy Market Surges in Response to Advancements in Gene Editing and IP Trends - ResearchAndMarkets.com

Retrieved on: 
木曜日, 10月 5, 2023
Health, Genetics, Other Science, Research, Science, Biotechnology, Patent, IP, IPSC, Abstract, Microsoft Excel, Traction, Graft-versus-host disease, Intellectual property, TALEN, Safety, Cancer, FDA, Allotransplantation, CRISPR, Growth, Database, European Patent Convention, CAR, Bone marrow, Gene editing, ZFN, NK, Attention, Vaccine, Pharmaceutical industry

The global allogeneic chimeric antigen receptor (CAR) cell therapy market is experiencing rapid growth, driven by intellectual property (IP) trends, advancements in gene editing tools, and emerging players entering the field.

Key Points: 
  • The global allogeneic chimeric antigen receptor (CAR) cell therapy market is experiencing rapid growth, driven by intellectual property (IP) trends, advancements in gene editing tools, and emerging players entering the field.
  • IP Trends Fuel Growth: The analysis of patent publications reveals that interest in allogeneic CAR therapies began in the late 2000s.
  • Advantages of Allogeneic CAR: Allogeneic CAR therapies offer several advantages over autologous CAR therapies, including faster production (10-11 days vs. over three weeks), scalability, standardization, and reduced manufacturing costs.
  • The report profiles key players in the allogeneic CAR cell therapy market, offering insights into their patent portfolios, geographical coverage, IP trends, and clinical trials.

Global Genome Editing Market Report 2023: Players Include Sangamo Therapeutics, Precision Biosciences, Cellectis, Merck and Lonza - ResearchAndMarkets.com

Retrieved on: 
金曜日, 6月 16, 2023
Health, Genetics, Genome Canada, Vaccine, CRISPR, DNA, ZFN, Biotechnology, Prevalence, Agriculture, COVID-19, MEA, Research, Medicine, Genomics, Genome, USD, Cas9, Forecasting, Government, Ministry, Incidence, Investment, Engineering, Plant growth analysis, Delivery, Mode, Growth, TALEN, Environment, Gene, Disease, Antibiotics, Fine chemical, Science, Application

As a result, the Genome Editing Market will increase favourably during the period of forecasting.

Key Points: 
  • As a result, the Genome Editing Market will increase favourably during the period of forecasting.
  • Recently, the market has grown primarily due to the expanding usage of CRISPR genome editing technology and increased demand for synthetic genes in various biotechnology fields.
  • The Global Genome Editing Market is segmented based on Technology, Delivery Method, Mode, End-use, Application, and Region.
  • Genome editing and engineering technologies have gained prominence because to the rising demand for vaccines and antiviral candidates; these reasons are anticipated to propel the genome editing market in the years to come.

Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event

Retrieved on: 
月曜日, 6月 5, 2023
Graft-versus-host disease, HD, Antigen, DNA, BP, TRAC, HSPC, Euronext Growth, Interferon gamma, UGI, CD19, Red blood cell, ISCT, Lymphoid leukemia, CD20, Neoplasm, Thymine, Patient derived xenograft, Survival, Gene editing, Bone marrow, CD52, CD22, Deamination, Toxicity, Cell, Stem cell, PDX, CAR, Patient, Risk, Engineering, International Society, Knowledge, HBB, TALEN, TC, Phenotype, Vaccine, Online shopping, Cosmetics, HBSS, Cellectis, Cytosine

The therapeutic options after CAR T-cell relapses are limited, emphasizing the need to develop novel therapies to improve current survival rates.

Key Points: 
  • The therapeutic options after CAR T-cell relapses are limited, emphasizing the need to develop novel therapies to improve current survival rates.
  • UCART20x22 is Cellectis’ first dual-targeting, allogeneic cell therapy product candidate targeting CD20 and CD22, to address the current challenges in the treatment of B-cell malignancies.
  • The oral presentation highlighted the following preclinical data:
    Robust in vitro and in vivo cytolytic activity against tumors expressing different antigen combinations.
  • The oral presentation is available on Cellectis’ website: https://www.cellectis.com/en/investors/scientific-presentations/
    Sickle cell disease stems from a single point mutation in the HBB gene which results in sickle hemoglobin.

Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy 

Retrieved on: 
水曜日, 3月 1, 2023
Knowledge, TALEN, Therapy, Cancer, Lymphocyte, Kite Pharma, Cell, CAR, Rearrangement, FDA, Gene editing, Patient, Food and Drug Administration, Food, Vaccine, Pharmaceutical industry

Gene editing is a common technique deployed to create allogeneic CAR T cells and other engineered cell therapy candidates.

Key Points: 
  • Gene editing is a common technique deployed to create allogeneic CAR T cells and other engineered cell therapy candidates.
  • Gene editing has the potential to induce chromosomal inversions as a consequence of post cleavage genetic recombination.
  • The Company’s case report details a chromosome 14 inversion in a patient treated with gene edited cells.
  • The rearrangement was not detectable in the manufacturing lots used to treat the patient or in any other lot manufactured by Allogene.

Genome Engineering Global Market Report 2022: Increasing Development of Novel Technologies Drives Growth - ResearchAndMarkets.com

Retrieved on: 
水曜日, 12月 14, 2022
Health, Genetics, MHRA, Biotechnology, Genome, NIH, Metabolic gene cluster, Pioneer program, Next Generation, Haemophilia, Drug discovery, DNA, Cancer, TALEN, Medicines and Healthcare products Regulatory Agency, Agriculture, Research, Precision medicine, Integration, CTA, Investment, Genetic engineering, Integrated DNA Technologies, Genomics, Growth, Medication, Application, ZFN, Sense (molecular biology), Antibiotics, Pharmaceutical industry, CRISPR

The global genome engineering market is anticipated to witness an impressive growth during the forecast period.

Key Points: 
  • The global genome engineering market is anticipated to witness an impressive growth during the forecast period.
  • The increasing funding and investments in the study and development of new genetic engineering technologies is expected to create lucrative opportunities for the growth of genome engineering market in the coming years.
  • This in turn will create lucrative opportunities for the growth of global genomic engineering market over the next few years.
  • In this report, Global Genome Engineering market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Cytovia Therapeutics Presents New Data on CD38-Targeted Flex-NK™ Bispecific Antibody at 2022 American Society of Hematology Annual Meeting

Retrieved on: 
金曜日, 12月 9, 2022
Lynx, Laboratory, Therapy, Ink, Multiple myeloma, National Cancer Institute, INSERM, Society, Cancer, Macrophage, Deep learning, CAR, Lymphatic system, Cornerstone, Natural killer T cell, BCMA, Standard of care, American Society of Hematology, Poster, Partnership, TALEN, Cell, Bone marrow, Multimedia, B cell, Immunotherapy, Transplant, Cellectis, Daratumumab, NK, Glioblastoma, Whole blood, CD38, Monoclonal antibody, Microfluidics, World Cancer Research Fund UK, ASH, Hematology, Protein, Patient, Research, UCSF, Survival, Death, Safety, HCC, CDC, Neoplasm, Vaccine, Pharmaceutical industry, ADCP, NCR1

"We're delighted to see further progress on our CD38-targeted Flex-NK bispecific antibody program, with a pre-clinical package that supports clinical evaluation in 2023," commented Cytovia CEO Dr.Daniel Teper.

Key Points: 
  • "We're delighted to see further progress on our CD38-targeted Flex-NK bispecific antibody program, with a pre-clinical package that supports clinical evaluation in 2023," commented Cytovia CEO Dr.Daniel Teper.
  • Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II
    The poster is available online on both the Cytovia Therapeutics and American Society of Hematology websites.
  • Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive iPSC-derived Natural Killer (iNK) cell and Flex-NK bispecific antibody platforms.
  • Cytovia has developed a partnership with CytoLynx Therapeutics focused on research and development, manufacturing, and commercialization activities inGreater Chinaand beyond.

Biosimilar Lymphocyte Modulator Global Market Report 2022: Featuring Pfizer, Biogen, Genentech, Novartis & Celltrion - ResearchAndMarkets.com

Retrieved on: 
月曜日, 11月 14, 2022
Health, General Health, Multiple myeloma, Immunotherapy, TILS, TALEN, Radiation, Breast cancer, Psoriasis, Approximation error, Enterocolitis, Lymphoma, George Washington University School of Medicine & Health Sciences, TIL, Disease, Washington University School of Medicine, Leukemia, Biosimilar, Methotrexate, CLL, USFDA, Society, Immune system, Alemtuzumab, Physician, Arthritis, Lymphatic system, Efalizumab, Diabetes, Growth, Multiple sclerosis, Etoposide, Patient, Health, Generic drug, Pharmaceutical industry, Cellectis

The "Biosimilar Lymphocyte Modulator Global Market Report 2022: By Drug, By Disease" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biosimilar Lymphocyte Modulator Global Market Report 2022: By Drug, By Disease" report has been added to ResearchAndMarkets.com's offering.
  • The main types of drugs in biosimilar lymphocyte modulator are campath-1H, natalizumab biosimilar, efalizumab - A1089-anti-CD11A biosimilar, anti-CD38 daratumumab biosimilar, anti-CS1 elotuzumab biosimilar.
  • The different diseases include arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, psoriasis, others
    Immunotherapy combined with other cancer treatments is expected to drive the growth of the biosimilar lymphocyte modulators market.
  • The shortage of raw material for lymphocyte modulator drugs is expected to restrict the growth of the biosimilar lymphocyte modulator market.

Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
月曜日, 11月 7, 2022
IOV, Patient, ORR, TIL, CRS, Private Securities Litigation Reform Act, RECIST, Risk, 2021 Essex County Council election, Perception, SAN, Food, PRS, Cancer, TIP, ICI, GLOBE, Society for Immunotherapy of Cancer, FDA, OS, Webcast, Safety, NSCLC, BLA, IRC, COVID-19, Cervical cancer, Data analysis, Immunotherapy, Investor, TALEN, MOS, Annual general meeting, Annual report, U.S. Securities and Exchange Commission, Clinical trial, Forward-looking statement, PSLRA, Life, NASDAQ, Disease, Concurrency, Security (finance), Time, Interleukin, Society, SITC, Food and Drug Administration, NR, BRAF, Pharmaceutical industry, Medical imaging, Iovance Biotherapeutics

SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the publication of abstracts reporting clinical data and a trial in progress (TIP) for Iovance tumor-infiltrating lymphocyte (TIL) cell therapies for the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 8-12, 2022, in Boston, MA and virtually.

Key Points: 
  • As previously reported, 100% of patients received prior anti-PD-1 therapy and more than 80% of patients received prior anti-CTLA-4 therapy.
  • Iovance senior leadership will be joined by key opinion leaders and principal investigators in Iovance clinical studies.
  • Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.
  • Our lead late-stage TIL product candidate, lifileucel for metastatic melanoma, has the potential to become the first approved one-time cell therapy for a solid tumor cancer.